60 Degrees Pharmaceuticals, Inc.
SXTP
$1.41
$0.118.46%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 144.95% | 89.43% | 512.18% | 16.80% | 100.80% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 144.95% | 89.43% | 512.18% | 16.80% | 100.80% |
| Cost of Revenue | -90.58% | 19.45% | -306.17% | 214.06% | 721.27% |
| Gross Profit | 100.26% | 15.97% | 335.93% | -334.21% | -840.71% |
| SG&A Expenses | 42.78% | 56.85% | -5.04% | -7.50% | 144.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -55.67% | 46.65% | 20.67% | 37.51% | 407.23% |
| Operating Income | 61.69% | -42.35% | -9.59% | -39.22% | -431.57% |
| Income Before Tax | 58.47% | -538.60% | -0.16% | -151.76% | -24.83% |
| Income Tax Expenses | 275.00% | 0.00% | -600.00% | 200.00% | 300.00% |
| Earnings from Continuing Operations | 58.44% | -538.62% | -0.13% | -151.77% | -24.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -20.00% | -68.00% | -88.50% | -92.78% | -78.57% |
| Net Income | 58.45% | -535.89% | -1.63% | -151.63% | -25.06% |
| EBIT | 61.69% | -42.35% | -9.59% | -39.22% | -431.57% |
| EBITDA | 62.06% | -42.01% | -9.35% | -39.44% | -438.99% |
| EPS Basic | 94.02% | -183.91% | 89.64% | -110.23% | 74.89% |
| Normalized Basic EPS | 94.28% | -157.10% | 89.33% | 74.02% | 64.07% |
| EPS Diluted | 94.02% | -183.91% | 89.64% | -110.23% | 74.89% |
| Normalized Diluted EPS | 94.28% | -157.10% | 89.33% | 74.02% | 64.07% |
| Average Basic Shares Outstanding | 625.57% | 660.37% | 885.36% | 445.31% | 412.63% |
| Average Diluted Shares Outstanding | 625.57% | 660.37% | 885.36% | 445.31% | 412.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |